Work

Phase II Study of Denileukin Diftitox (ONTAK®) in Patients with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (B-NHL) and Poor Bone Marrow Reserve.

Year: 2006

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v108.11.4724.4724

Authors: Myron S. Czuczman, Lauren Pinter-Brown, Mary Jo Lechowicz, Nancy Bartlett, Hillard Lazarus, John Lister, Andre Goy, Stephen Kahanic, Peter Rosen, Mark Acosta

Institutions: Roswell Park Comprehensive Cancer Center, University of California, Los Angeles, Ronald Reagan UCLA Medical Center, UCLA Medical Center, Emory University, Winship Cancer Institute, Washington University in St. Louis, University Hospitals of Cleveland, Western Pennsylvania Hospital, Hackensack University Medical Center, Tower Cancer Research Foundation, Ligand Pharmaceuticals (United States)

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2556564088

FWCI:

Cites:

Cited by:

Related to: 10